CANF Stock Risk & Deep Value Analysis
Can Fite Biopharma Ltd
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About CANF Stock
We analyzed Can Fite Biopharma Ltd using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran CANF through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
CANF Risk Analysis & Red Flags
What Could Go Wrong
The company is burning cash and relies heavily on dilutive financing. If ongoing clinical trials fail to produce sufficiently strong data, or if the company cannot attract a major pharmaceutical partner for later-stage development, it will likely face severe financial distress, inability to fund future trials, and significant further shareholder dilution, potentially leading to a massive loss of investment value or even delisting.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
High
Execution
High
Regulatory
High
Red Flags
- ⚠
Declining revenue (40% YoY in 2025) and worsening net loss ($9.83M in 2025).
- ⚠
Reliance on highly dilutive equity offerings (warrant exercises) for funding operations.
- ⚠
Cash position, while recently improved by $4.3M, remains limited (~$12.84M) for extensive Phase 3 trials.
- ⚠
No analyst coverage or institutional ownership information reported.
Upcoming Risk Events
- 📅
Negative or inconclusive clinical trial results for Namodenoson or Piclidenoson
- 📅
Inability to secure further funding for clinical trials, leading to operational delays or cessation
- 📅
Increased dilution from future equity raises
When to Reconsider
- 🚪
Failure to meet key clinical endpoints in ongoing Namodenoson trials.
- 🚪
Announcements of significant further dilution (e.g., reverse stock split + new offering) without concurrent major partnership.
- 🚪
Cash balance falls below $5M with no clear path to additional funding.
Unlock CANF Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Can Fite Biopharma Ltd (CANF) Do?
Market Cap
$7.09M
Sector
Healthcare
Industry
Biotechnology
Employees
5
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.
Visit Can Fite Biopharma Ltd WebsiteInvestment Thesis
Can-Fite is a highly speculative, deep-value biotech play positioned for potential significant upside if its lead drug candidates, Namodenoson (pancreatic cancer, HCC, NASH) and Piclidenoson (inflammatory diseases, animal health), achieve successful clinical milestones and attract major pharmaceutical partnerships. The recent positive clinical updates for both assets and improved short-term liquidity provide a glimmer of hope amidst severe financial challenges, targeting huge unmet medical needs.
Is CANF Stock Undervalued?
Unlock the full AI analysis for CANF
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
CANF Price Targets & Strategy
12-Month Target
$4.50
Bull Case
$7.50
Bear Case
$1.00
Valuation Basis
Highly speculative, based on improved clinical pipeline outlook for Namodenoson and Piclidenoson, potentially attracting partnership interest or stronger investor confidence, pushing market cap to $30M-$40M in 12 months.
Entry Strategy
Only for aggressive, speculative investors. Dollar-cost average on dips below $2.50.
Exit Strategy
Take 50% profit at $5.00; Stop loss at $2.00 to protect capital.
Portfolio Allocation
0.5-1% for highly aggressive, speculative portion of a portfolio.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is CANF Financially Healthy?
Valuation
P/E Ratio
-1.90
PEG Ratio
-0.05
Price/Book
2.80
Price/Sales
22.60
Balance Sheet
Current Ratio
3.60
Debt/Equity
0.02
Cash & Equivalents
$8.54M
Does CANF Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Eroding
Moat Sources
1 Identified
The durability of Can-Fite's intellectual property (IP) is highly uncertain. While patents exist for its drug candidates, their commercial value depends entirely on successful, costly, and high-risk clinical development through Phase 3 trials and regulatory approval. Intense competition from larger, better-funded pharmaceutical companies and the inherent high failure rate of drug development make the IP moat fragile.
Moat Erosion Risks
- •Failure in late-stage clinical trials for lead candidates.
- •Emergence of superior or more cost-effective treatments from competitors.
- •Inability to secure sufficient funding to complete clinical development and commercialization.
CANF Competitive Moat Analysis
Sign up to see competitive advantages
CANF Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral
Institutional Sentiment
Negative
Insider Activity (Form 4)
Director Abraham Sartani filed Form 3 on April 6, 2026, detailing existing vested/unvested stock options (16,000 shares at $2.18/share vesting through 2030). No insider buys or sells in the last 90 days.
Options Flow
Normal options activity
Earnings Intelligence
Next Earnings
Estimated early-May 2026
Surprise Probability
Low
Historical Earnings Pattern
Not enough data to establish a clear pattern; likely highly sensitive to clinical news flow rather than quarterly financial performance alone.
Key Metrics to Watch
Competitive Position
Top Competitor
Not specified in data, but large pharma like Roche/Gilead for cancer/NASH.
Market Share Trend
Losing
Valuation vs Peers
No comparable valuations available; trading at a deep discount if pipeline succeeds, or zero if it fails.
Competitive Advantages
- •Proprietary A3 adenosine receptor modulation technology for lead candidates.
- •Early-stage clinical data in high-unmet-need cancer indications (pancreatic cancer, HCC).
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive CANF Stock Higher?
Near-Term (0-6 months)
- •Piclidenoson Phase 2 (dogs) osteoarthritis study data expected Q3 2026
- •Further clinical updates on Namodenoson Phase 2a pancreatic cancer trial
- •Q1 2026 earnings report (estimated early-May 2026)
Medium-Term (6-18 months)
- •Potential advancement of Namodenoson into Phase 2/3 for NASH or HCC
- •Potential human pharma partnership discussions for Namodenoson or Piclidenoson
- •Development of preclinical programs
Long-Term (18+ months)
- •Major regulatory approvals for lead candidates (Namodenoson, Piclidenoson)
- •Significant milestone payments from partnerships or direct product sales
- •Market entry for Namodenoson in a large indication like liver cancer or NASH
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for CANF?
- ✓
Positive efficacy data from Piclidenoson Phase 2 dog study (Q3 2026).
- ✓
Advancement of Namodenoson to larger, later-stage clinical trials for human indications.
- ✓
Announcement of a significant human pharma partnership or licensing deal.
Bull Case Analysis
See what could go right with Premium
Competing with CANF
See how Can Fite Biopharma Ltd compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Can Fite Biopharma Ltd CANF | $7.1M | 2.1 | -1.9 | $410,000 | 0.0% | -40.0% | |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Can Fite Biopharma Ltd Makes Money
Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company focused on developing small molecule drugs that modulate the A3 adenosine receptor for the treatment of inflammatory diseases, cancer, and liver diseases. Currently, it generates very limited revenue, primarily through early-stage licensing agreements or niche commercialization (e.g., animal health via Vetbiolix). Its core business model relies on the successful development, regulatory approval, and eventual commercialization or licensing of its proprietary drug candidates, specifically Namodenoson and Piclidenoson, to generate significant future revenues through product sales or milestone and royalty payments from partners.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Can Fite Biopharma Ltd (CANF)?
As of April 8, 2026, Can Fite Biopharma Ltd has a DVR Score of 2.1 out of 10, placing it in the "Risk Trap" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Can Fite Biopharma Ltd?
Can Fite Biopharma Ltd's market capitalization is approximately $7.1M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Can Fite Biopharma Ltd use?
CANF is the ticker symbol for Can Fite Biopharma Ltd. The company trades on the ASE.
What is the risk level for CANF stock?
Our analysis rates Can Fite Biopharma Ltd's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of CANF?
Can Fite Biopharma Ltd currently has a price-to-earnings (P/E) ratio of -1.9. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Can Fite Biopharma Ltd's revenue growing?
Can Fite Biopharma Ltd has reported revenue growth of -40.0%. Revenue has been declining, which warrants closer examination.
Is CANF stock profitable?
Can Fite Biopharma Ltd has a profit margin of 0.0%. The company is currently unprofitable.
How often is the CANF DVR analysis updated?
Our AI-powered analysis of Can Fite Biopharma Ltd is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 8, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for CANF (Can Fite Biopharma Ltd) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.